New Alzheimer’s Drug Slows Cognitive Decline in Clinical Trial
New Alzheimer’s Drug Slows Cognitive Decline in Clinical Trial
The Biogen-developed treatment, called lecanemab, appears to have a more clear-cut effect on slowing the disease than the company’s previous Alzheimer’s drug, Aduhelm.
The Biogen-developed treatment, called lecanemab, appears to have a more clear-cut effect on slowing the disease than the company’s previous Alzheimer’s drug, Aduhelm.
biogen
Lawmakers Request Information About Alzheimer’s Drug Approval
Annie Melchor | Sep 3, 2021 | 3 min read
The FDA granted the drug, called Aduhelm, accelerated approval earlier this summer in a process that’s since drawn scrutiny.
Conference Linked to as Many as 300,000 COVID-19 Cases: Study
Lisa Winter | Dec 14, 2020 | 2 min read
Around 100 people were infected at a scientific meeting hosted by Biogen in Boston in February. Then they went back home, taking the virus with them.
Thousands of Coronavirus Infections Stemmed from a Biotech Event
Amanda Heidt | Aug 26, 2020 | 3 min read
Officials had initially linked 97 cases to a single conference held by Biogen in February in Boston, but a new study tracking viral genomes suggests the number may be as high as 20,000.
Biogen Uses its Own Superspreader Event to Aid COVID-19 Research
Claire Jarvis | May 19, 2020 | 3 min read
A blood biobank allows scientists to study the immune responses to the coronavirus among infected Biogen employees and their contacts.